Stay informed and receive company updates straight to your inbox.
Our lead product, Leronlimab (PRO 140), is the world’s first self-injectable, subcutaneous injection for HIV and has many advantages over the current standard of care, HAART, including no serious side effects, enhanced compliance, and longer half-life.Read More on Leronlimab
Recent research demonstrated the importance of CCR5 in cancer indications and indicates that Leronlimab (PRO 140) is a potential inhibitor of the CCR5 receptor.Read More on CCR5
Graft-versus-host disease (GVHD) is a serious complication that limits the use of Bone Marrow Stem Cell (BMSC) transplantation in patients with blood cancers. Our current clinical trial studies Leronlimab for the prevention of GVHD in patients (RIC) undergoing BMSC transplantation.Read More on GVHD
CytoDyn is coordinating with several healthcare partners to provide access to leronlimab for COVID-19 patients through two clinical trials, a Phase 2 trial for those with mild-to-moderate indications and a Phase 2b/3 trial for severe and critically ill patients.Read More on COVID-19